Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Revance Therapeutics, Inc. | Director | Common Stock | 322 K | $2.4 M | $7.47 | Mar 15, 2022 | Aubrey and Luanne Rankin Revocable Living Trust Dated July 1, 2009 |
Revance Therapeutics, Inc. | Director | Common Stock | 154 K | $1.15 M | $7.47 | Mar 15, 2022 | The Rankin Irrevocable Trust |
Revance Therapeutics, Inc. | Director | Common Stock | 94.1 K | $703 K | $7.47 | Mar 15, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
RVNC | Revance Therapeutics, Inc. | Mar 15, 2022 | 1 | -$21.7 K | 4 | Mar 17, 2022 | Director |
RVNC | Revance Therapeutics, Inc. | Dec 3, 2021 | 1 | $433 K | 4 | Dec 6, 2021 | President, Innovation & Tech, Director |
RVNC | Revance Therapeutics, Inc. | Aug 15, 2021 | 2 | -$375 K | 4 | Aug 17, 2021 | President, Innovation & Tech, Director |
RVNC | Revance Therapeutics, Inc. | Jul 28, 2021 | 2 | -$1.63 M | 4 | Jul 30, 2021 | President, Innovation & Tech, Director |
RVNC | Revance Therapeutics, Inc. | Jul 26, 2021 | 1 | -$1.65 M | 4 | Jul 28, 2021 | President, Innovation & Tech, Director |